Category: Drug Development
Fax: +1 (617) 663-6139
Location: Natick, MA
Therapeutic Areas: Allergy, Autoimmune/Inflammatory, Blood Disorder, Cancer/Oncology, HIV Infections, Immune System, Inflammation, Ophthalmology
Karyopharm Therapeutics, a privately held Natick, Mass-based Biopharmaceutical Company, is focused on the development of novel drugs for the treatment of cancer, inflammation, HIV, ophthalmic and other diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways (e.g. FOXO, NFKB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company uses its unique technology platform, developed by Dr. Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and to evaluate them in subsequent human clinical studies.
Karyopharm Therapeutics first target, Crm1 is the main exporter of key tumor suppressor proteins and was found to be correlated with poor prognosis in cervical, ovarian, liver cancers, osteosarcoma, and gliomas.
Karyopharm Therapeutics goal is to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture that will accelerate small molecule modulators of nuclear transport into effective therapeutics for life threatening conditions.